UK set to produce 70 percent of PPE required domestically by December
Due to the demand caused by the COVID-19 pandemic, the UK government has said British manufacturers will produce the majority of PPE by the end of the year.
List view / Grid view
News
Demand for CROs expected to revive business activity to pre-pandemic levels
A new report has said that CROs are likely to resume their business activity in the second half of 2020 because of high demand.
Older people likely to be underrepresented in COVID-19 trials, says study
Researchers suggest, based on certain exclusions, older people are likely to be underrepresented in 50 percent of COVID-19 trials and all vaccine trials in the US.
Has pharma abused the US COVID-19 small business loans system?
A review suggests some large pharma companies were approved to receive paycheck protection program (PPP) loans that were intended to help small US businesses to pay workers during the COVID-19 pandemic.
Global HPAPI market to grow at CAGR of 8.7 percent by 2026
A report has said that the highly potent compound market will grow to be worth $32,200 million by the end of 2026.
Novavax begins Phase III COVID-19 vaccine efficacy trial
The trial will evaluate the safety and efficacy of the Novavax’ NVX-CoV2373 vaccine candidate in approximately 10,000 UK participants.
UK and EU pharma call for medicines to be prioritised in Brexit trade talks
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
Importance of sublimation tests when freeze-drying HPAPIs shown in study
Researchers have shown that sublimation tests should be conducted if new components are added to the freeze-drying process of HPAPIs.
Phase III trial of J&J COVID-19 vaccine candidate enrols first volunteers
A Phase III clinical trial to evaluate J&J's COVID-19 vaccine in multiple countries has enrolled its first patients.
Research finds 25 percent of drugs contain highly potent compounds
A new report has said that a quarter of drugs globally are based on highly potent active pharmaceutical ingredients.
EU to receive 300 million COVID-19 vaccine doses from Sanofi and GSK
A contract for 300 doses of the investigational COVID-19 vaccine candidate has been signed by the European Commission (EC).
EUA requested for potential COVID-19 respiratory failure treatment
An Emergency Use Authorization (EUA) request for the use of RLF-100™ (aviptadil) in critical COVID-19 patients was submitted to the US FDA.
Global anti-counterfeit packaging market to grow to $17.47 billion
Growth in the anti-counterfeit technologies market will be particularly large in the pharma industry due to increasing awareness around health and safety, says report.
Serum Institute of India: outsourced manufacturing of COVID-19 vaccines
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
Herd immunity is an impractical COVID-19 mitigation strategy, says study
Researchers who designed a transmission model for COVID-19 demonstrated that attempting to establish herd immunity against COVID-19 would be too challenging.
